Oxford Biomedica Holds Full-Year Revenue Guidance Despite Wider Loss

Oxford Biomedica kept its reduced full-year revenue guidance unchanged on Tuesday, citing a growing customer base, while reporting a wider first-half loss for the six months ended 30 June.

Revenue climbed 9.2% to £79.9m from £73.2m a year earlier, or 10% at constant currency. But the cost of sales rose far more quickly, up 22% to £50.7m from £41.6m, and the group recorded a £7.6m asset impairment that had no equivalent a year earlier. Pretax loss widened to £36.2m from £26.0m; finance income fell to £1.8m from £4.4m while finance costs rose to £9.0m from £6.9m. Diluted loss per share increased to 30.39 pence from 25.35 pence.

The customer pipeline was the main positive signal. Oxford Biomedica signed 17 new clients in the half-year, more than 30% above the total number signed across the whole of 2025, and added a further four contracts after the period ended. Its total portfolio now comprises 59 customer programmes across 50 customers. At 30 June, the revenue portfolio was about £193m, with £168m of expected 2026 revenue already covered by contracted customer orders.

Management reiterated full-year constant-currency revenue guidance of £180m to £200m, the level to which it was lowered in August from £220m to £240m. The company also repeated guidance for a 2026 EBITDA margin in the mid-single digits excluding one-offs, and in the low-single digits on a reported basis. Oxford Biomedica shares rose 0.4% to 466.91 pence in London on Tuesday morning.

What Oxford Biomedica's Order Book and Cost Strain Reveal

Customer Wins Are Outpacing Profit Recovery

The 17 new clients signed in the half-year point to real commercial momentum, but the income statement shows that revenue growth is not yet offsetting rising costs. Cost of sales increased 22% against revenue growth of 9.2%, meaning the gross margin narrowed. The £7.6m impairment also indicates that some asset values were written down, although the source does not specify which assets. Until higher-margin work scales or costs per programme fall, stronger customer numbers may not translate into narrower losses.

How Much of the Guidance Is Already Contracted

At 30 June, £168m of the £180m–£200m full-year forecast was already covered by contracted customer orders, equivalent to roughly 84%–93% of the target range. This contracted cover is the main reason management can maintain its outlook despite the wider loss. Still, the company must deliver those orders and secure enough additional work to reach at least the lower end. H2 revenue would need to be approximately £100.1m–£120.1m, compared with £79.9m recorded in H1.

The 2030 Ambition Is a Long-Way Scenario

Management points to an expanding customer base, increasing visibility and maturing programmes as support for a £500m revenue ambition by 2030 and long-term EBITDA margins approaching 30%. That is a considerable step-up from the current scale and is not demonstrated by H1 profitability. CEO Frank Mathias said demand for the group's differentiated capabilities is clear, but the evidence in this update is mainly pipeline growth rather than delivered margin expansion.

What the H1 Results Imply for Oxford Biomedica Investors

For investors and analysts, the H1 update mostly confirms the lower guidance and shifts attention to contract conversion and cost discipline in the second half.

  • Compare the remaining H2 revenue requirement of £100.1m to £120.1m against H1's £79.9m with the £168m in contracted customer orders reported at 30 June; the difference shows how much new business must convert during H2 to meet the reiterated £180m–£200m guidance.
  • Assess whether the 22% jump in cost of sales to £50.7m persists, since management's mid-single-digit EBITDA margin target for 2026 excludes one-off costs and reported margins are guided only to the low-single digits after the £7.6m impairment already booked.
  • Treat the 2027 revenue growth target of 25%–30% and the 2030 revenue ambition of £500m as company scenarios rather than confirmed demand; the current order book is supported by 59 customer programmes and 50 customers, but the H1 loss shows margin delivery has not yet caught up with customer acquisition.
  • For existing or prospective CDMO clients, the 17 first-half client wins and four post-period additions indicate usable manufacturing and development capacity; contract terms, delivery timelines and programme economics are the operational issues to clarify directly with Oxford Biomedica.

Risk & Opportunity Assessment

Commercial RiskMediumOxford Biomedica reiterated £180m–£200m full-year revenue guidance and has £168m of 2026 revenue under contracted customer orders, but H1 showed a 22% rise in cost of sales and a £7.6m impairment; H2 delivery is still required to hit the target.
Competitive RiskLowThe release names no competitor and reports 17 new H1 client wins plus four post-period additions; there is no evidence in the stated figures of competitive displacement or lost programmes.
Regulatory RiskLowNo regulatory, licensing or pricing decision is mentioned in the half-year update; regulation is not a driver of the reported loss or guidance.
Reputation RiskMediumThe August guidance cut from £220m–£240m to £180m–£200m and a widening first-half loss could temper investor confidence, although the maintained outlook and stable share price suggest the market had partly priced in the weaker trend.
Technology DisruptionLowThe update includes no specific technological failure or platform change; management frames demand around the maturing cell and gene therapy market rather than a disruptive technology shift.
Commercial OpportunityHighOxford Biomedica added 17 new clients in H1, more than 30% above its full-year 2025 total, added four more after period end, and holds a £193m revenue portfolio with £168m contracted for 2026; these provide a concrete near-term growth path toward the 2027 and 2030 targets.